UNLABELLED: Posttraumatic stress disorder (PTSD) is an important syndrome among military veterans. Little has been written about comorbid medical conditions of PTSD, particularly overweight and obesity. We focus on psychotropic and non-psychotropic drugs, their interactions, and metabolic issues most relevant to primary care physicians. METHOD: Data from the recently constituted PTSD program at the Department of Veterans Affairs Medical Center in Richmond, Va., were retrospectively reviewed to assess the prevalence and severity of comorbid overweight and obesity in male veterans with PTSD. Also, our database allowed us to correlate various drugs used to treat hypertension, diabetes mellitus, and dyslipidemia with body mass index (BMI). RESULTS: The mean BMI of 157 veterans with PTSD (DSM-IV criteria) in this sample was in the obese range (30.3 ± 5.6 kg/m²). The number of drugs a given patient was taking for treatment of hypertension, diabetes mellitus, and dyslipidemia correlated with BMI. Psychotropic drugs associated with weight gain did not explain our findings. CONCLUSIONS: Overweight and obesity among our male veterans with PTSD strikingly exceeded national findings. The administration of psychotropic drugs associated with weight gain did not explain these findings. The number of medications used to treat hypertension, diabetes mellitus, and dyslipidemia correlated significantly with BMI. Rather than these medications explaining the high prevalence of overweight and obesity in our study population, obesity probably worsened these components of the metabolic syndrome, necessitating more aggressive treatment reflected in the high number of drugs prescribed.
UNLABELLED: Posttraumatic stress disorder (PTSD) is an important syndrome among military veterans. Little has been written about comorbid medical conditions of PTSD, particularly overweight and obesity. We focus on psychotropic and non-psychotropic drugs, their interactions, and metabolic issues most relevant to primary care physicians. METHOD: Data from the recently constituted PTSD program at the Department of Veterans Affairs Medical Center in Richmond, Va., were retrospectively reviewed to assess the prevalence and severity of comorbid overweight and obesity in male veterans with PTSD. Also, our database allowed us to correlate various drugs used to treat hypertension, diabetes mellitus, and dyslipidemia with body mass index (BMI). RESULTS: The mean BMI of 157 veterans with PTSD (DSM-IV criteria) in this sample was in the obese range (30.3 ± 5.6 kg/m²). The number of drugs a given patient was taking for treatment of hypertension, diabetes mellitus, and dyslipidemia correlated with BMI. Psychotropic drugs associated with weight gain did not explain our findings. CONCLUSIONS: Overweight and obesity among our male veterans with PTSD strikingly exceeded national findings. The administration of psychotropic drugs associated with weight gain did not explain these findings. The number of medications used to treat hypertension, diabetes mellitus, and dyslipidemia correlated significantly with BMI. Rather than these medications explaining the high prevalence of overweight and obesity in our study population, obesity probably worsened these components of the metabolic syndrome, necessitating more aggressive treatment reflected in the high number of drugs prescribed.
Authors: Ali H Mokdad; Earl S Ford; Barbara A Bowman; William H Dietz; Frank Vinicor; Virginia S Bales; James S Marks Journal: JAMA Date: 2003-01-01 Impact factor: 56.272
Authors: Sandeep R Das; Linda S Kinsinger; William S Yancy; Anthea Wang; Eileen Ciesco; Mary Burdick; Steven J Yevich Journal: Am J Prev Med Date: 2005-04 Impact factor: 5.043
Authors: W Victor R Vieweg; Lisa J Kuhnley; E John Kuhnley; Emmanuel A Anum; Bela Sood; Anand Pandurangi; Joel J Silverman Journal: Prog Neuropsychopharmacol Biol Psychiatry Date: 2005-03-21 Impact factor: 5.067
Authors: A Martin; J Landau; P Leebens; K Ulizio; D Cicchetti; L Scahill; J F Leckman Journal: J Child Adolesc Psychopharmacol Date: 2000 Impact factor: 2.576
Authors: M Tohen; T G Jacobs; S L Grundy; S L McElroy; M C Banov; P G Janicak; T Sanger; R Risser; F Zhang; V Toma; J Francis; G D Tollefson; A Breier Journal: Arch Gen Psychiatry Date: 2000-09
Authors: M Tohen; T M Sanger; S L McElroy; G D Tollefson; K N Chengappa; D G Daniel; F Petty; F Centorrino; R Wang; S L Grundy; M G Greaney; T G Jacobs; S R David; V Toma Journal: Am J Psychiatry Date: 1999-05 Impact factor: 18.112
Authors: Robin M Masheb; Amanda M Kutz; Alison G Marsh; Kathryn M Min; Christopher B Ruser; Lindsey M Dorflinger Journal: Eat Weight Disord Date: 2019-08-30 Impact factor: 4.652
Authors: Lisa M Kinoshita; Jerome A Yesavage; Art Noda; Booil Jo; Beatriz Hernandez; Joy Taylor; Jamie M Zeitzer; Leah Friedman; J Kaci Fairchild; Jauhtai Cheng; Ware Kuschner; Ruth O'Hara; Jon-Erik C Holty; Blake K Scanlon Journal: Sleep Breath Date: 2011-12-23 Impact factor: 2.816
Authors: T W McGlennon; J N Buchwald; Walter J Pories; Fang Yu; Arthur Roberts; Eric P Ahnfeldt; Rukmini Menon; Henry Buchwald Journal: Obes Surg Date: 2020-10-30 Impact factor: 4.129
Authors: Hua Jin; Nicole M Lanouette; Sunder Mudaliar; Robert Henry; David P Folsom; Srikriskna Khandrika; Danielle K Glorioso; Dilip V Jeste Journal: J Clin Psychopharmacol Date: 2009-06 Impact factor: 3.153